Landfar Bio-medicine Co., Ltd (SHE:000504)
China
· Delayed Price · Currency is CNY 9.19
-0.30 (-3.16%)
Apr 30, 2026, 12:04 PM CST
Landfar Bio-medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 18.05 | -19.85 | -28.17 | -12.46 | -19.13 | Upgrade
|
| Depreciation & Amortization | 7.41 | 5.7 | 6.34 | 6.21 | 6.87 | Upgrade
|
| Other Amortization | 23.94 | 12.19 | 9.15 | 9.1 | 7.26 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0 | -0.16 | -11.9 | -0.08 | -0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 2.73 | 0.47 | 6.92 | 0.9 | 2.53 | Upgrade
|
| Loss (Gain) From Sale of Investments | -7.87 | -3.68 | -0.95 | 0.06 | 0.31 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 12.3 | 26.08 | 23.79 | 17.11 | Upgrade
|
| Other Operating Activities | 16.87 | 7.47 | -0.13 | -2.39 | 0.38 | Upgrade
|
| Change in Accounts Receivable | -173.67 | -37.38 | 9.84 | 135.21 | 47.24 | Upgrade
|
| Change in Inventory | 2.58 | -25.41 | -6.18 | 4.82 | 4.29 | Upgrade
|
| Change in Accounts Payable | -4.86 | 54.04 | 25.96 | 1 | 40.89 | Upgrade
|
| Operating Cash Flow | -115.74 | 4.79 | 36.28 | 166.38 | 107.1 | Upgrade
|
| Operating Cash Flow Growth | - | -86.79% | -78.20% | 55.35% | - | Upgrade
|
| Capital Expenditures | -5.12 | -18.26 | -5.92 | -16.94 | -31.96 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0 | 17.72 | 0.33 | 0.07 | Upgrade
|
| Cash Acquisitions | -61.23 | 2.53 | - | - | - | Upgrade
|
| Investment in Securities | 100 | -98.19 | 0.95 | 0.49 | 0 | Upgrade
|
| Other Investing Activities | -6.78 | 5.59 | - | - | 1.74 | Upgrade
|
| Investing Cash Flow | 26.89 | -108.33 | 12.75 | -16.12 | -30.15 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 75.14 | 55.86 | Upgrade
|
| Long-Term Debt Issued | 22.3 | 18 | 28 | - | - | Upgrade
|
| Total Debt Issued | 22.3 | 18 | 28 | 75.14 | 55.86 | Upgrade
|
| Short-Term Debt Repaid | - | -159.79 | -3.77 | -145 | -41.96 | Upgrade
|
| Long-Term Debt Repaid | -33.52 | -39.54 | -66.97 | -3.17 | -3.24 | Upgrade
|
| Total Debt Repaid | -33.52 | -199.33 | -70.74 | -148.17 | -45.2 | Upgrade
|
| Net Debt Issued (Repaid) | -11.22 | -181.33 | -42.74 | -73.03 | 10.66 | Upgrade
|
| Issuance of Common Stock | - | - | 273.7 | - | - | Upgrade
|
| Common Dividends Paid | -2.37 | -0.93 | -3.21 | -2.4 | -2.12 | Upgrade
|
| Other Financing Activities | 241.86 | -0.65 | -1.12 | -9.72 | 0.47 | Upgrade
|
| Financing Cash Flow | 228.28 | -182.91 | 226.63 | -85.15 | 9.02 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0 | 0 | 0 | 0 | 0 | Upgrade
|
| Net Cash Flow | 139.43 | -286.45 | 275.66 | 65.11 | 85.97 | Upgrade
|
| Free Cash Flow | -120.85 | -13.47 | 30.36 | 149.44 | 75.14 | Upgrade
|
| Free Cash Flow Growth | - | - | -79.68% | 98.89% | - | Upgrade
|
| Free Cash Flow Margin | -29.06% | -10.02% | 22.19% | 74.59% | 47.97% | Upgrade
|
| Free Cash Flow Per Share | -0.38 | -0.04 | 0.10 | 0.48 | 0.24 | Upgrade
|
| Cash Interest Paid | - | - | - | - | 0.13 | Upgrade
|
| Cash Income Tax Paid | 20.48 | 10.71 | 18.25 | 9.24 | 16.06 | Upgrade
|
| Levered Free Cash Flow | -193.46 | -6.16 | 44.79 | 148.96 | 94.32 | Upgrade
|
| Unlevered Free Cash Flow | -193.46 | -5.24 | 51.71 | 157.03 | 104.3 | Upgrade
|
| Change in Working Capital | -176.86 | -9.65 | 28.94 | 141.25 | 91.79 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.